Patents Examined by Ernst V. Arnold
-
Patent number: 11969521Abstract: A bone-regeneration material that contains calcium phosphate particles in a biodegradable fiber containing PLGA by using electrospinning. A PLGA resin is heated in a kneader to soften until the viscosity of the resin becomes 102 to 107 Pa·s. A powder of calcium phosphate fine particles is added and mixed with the softened PLGA resin, while the blade of the kneader rotates. The mixture is kneaded by applying thermal and mechanical energy to the mixture through the continuous rotation of the blade of the kneader in the heated state, and aggregations of the calcium phosphate fine particles are disintegrated to prepare a composite in which the calcium phosphate fine particles are dispersed in the PLGA resin. The composite is dissolved in a solvent to prepare a spinning solution. Electrospinning is performed on the spinning solution to manufacture biodegradable fibers having therein the calcium phosphate fine particles substantially uniformly dispersed.Type: GrantFiled: April 3, 2020Date of Patent: April 30, 2024Assignees: NATIONAL UNIVERSITY CORPORATION NAGOYA INSTITUTE OF TECHNOLOGY, ORTHOREBIRTH CO., LTD.Inventors: Toshihiro Kasuga, Yasutoshi Nishikawa
-
Patent number: 11938223Abstract: Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.Type: GrantFiled: July 7, 2022Date of Patent: March 26, 2024Assignee: Incept, LLCInventors: Peter Jarrett, Michael J. McGrath, Timothy S. Jarrett, Rami El-Hayek, Andrew C. Vanslette, Courtney A Rosales, Charles D. Blizzard, Amarpreet S. Sawhney
-
Patent number: 11931377Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.Type: GrantFiled: April 8, 2019Date of Patent: March 19, 2024Assignee: Mallinckrodt Hospital Products IP LimitedInventor: James S. Baldassarre
-
Patent number: 11931464Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.Type: GrantFiled: July 28, 2021Date of Patent: March 19, 2024Assignee: Catalent U.K. Swindon Zydis LimitedInventors: Rosaleen McLaughlin, Simon Andrew Martyn Howes, Craig Wheadon, Jonathon Whitehouse, Adam Parker
-
Patent number: 11925764Abstract: A method for delivering nitric oxide therapy to a subject can include administering a composition including a nitric-oxide releasing agent and silica to the subject and releasing a therapeutic amount of nitric oxide from the composition.Type: GrantFiled: August 30, 2021Date of Patent: March 12, 2024Assignee: VERO Biotech Inc.Inventor: David H. Fine
-
Patent number: 11918654Abstract: The present specification discloses solid solution pharmaceutical compositions comprising therapeutic compound comprising a phytocannabinoid in an amount of less than about 55%, one or more pharmaceutically-acceptable hard fats in an amount of at least 25% by weight of the pharmaceutical composition, and one or more pharmaceutically-acceptable liquid lipids in an amount of 1% to 50% by weight of the pharmaceutical composition, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: GrantFiled: December 28, 2021Date of Patent: March 5, 2024Assignee: Infirst Healthcare LimitedInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Patent number: 11919990Abstract: The invention related to a one-pot process of making a single-phase silicone-acrylic hybrid adhesive composition comprising acrylic polymer and silicone polymer that are covalently bonded through a —Si—O—Si— linkage. The acrylic polymer contains at least one hydrolyzable silane (meth)acrylic monomer or siloxane (meth)acrylic macromer. These functional moieties provide reaction sites to form —Si—O—Si— bond by reacting hydrolyzable groups in the silicone polymer in the presence of a base or acid catalyst and water. The formed covalent bonds between the two incompatible systems of silicone polymer and acrylic polymer prevents phase separation and thereby a permanent, homogeneous single-phase system is formed.Type: GrantFiled: October 1, 2020Date of Patent: March 5, 2024Assignee: HENKEL AG & CO. KGaAInventor: Yuxia Liu
-
Patent number: 11911399Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.Type: GrantFiled: March 2, 2021Date of Patent: February 27, 2024Assignee: The Cleveland Clinic FoundationInventor: Stanley L. Hazen
-
Patent number: 11890396Abstract: Provided herein is a living bone graft including a biofabricated graft core including demineralized bone matrix and a carrier and a pre-vascularized shell at least partially enrobing the graft core, the pre-vascularized shell including isolated, intact adipose-derived microvessel fragments, mesenchymal stem cells, and collagen. The disclosed bone grafts include stromal cells that differentiate and microvessels that inosculate to provide a functional microvasculature, thereby approximating native bone repair as the graft matures in the patient. Also provided herein are methods of fabricating a bespoke, living, vascularized bone graft and methods of treating a segmental bone defect in a patient.Type: GrantFiled: October 9, 2020Date of Patent: February 6, 2024Assignee: Advanced Solutions Life Sciences, LLCInventors: James B. Hoying, Sarah Moss
-
Patent number: 11883392Abstract: According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.Type: GrantFiled: February 10, 2021Date of Patent: January 30, 2024Assignee: OREXO ABInventors: Jonas Sävmarker, Robert Rönn, Andreas Fischer
-
Patent number: 11879034Abstract: The disclosure provides a method of preparing a polymer scaffold including admixing a biotinylated reagent and a polymer to form a biotinylated polymer, subjecting the biotinylated polymer to conditions sufficient to form the polymer scaffold and optionally admixing the polymer scaffold with a streptavidin-modified biomolecule to form a biomolecule-modified polymer scaffold. The disclosure further provides a method of preparing a polymer scaffold including admixing a first click chemistry reagent and a poly(lactic-co-glycolic acid) (PLGA) polymer to form a modified PLGA polymer, subjecting the modified PLGA polymer to conditions sufficient to form the polymer scaffold, and optionally admixing the polymer scaffold with a biomolecule modified to include a second click chemistry reagent that selectively reacts with the first click chemistry reagent, to form a biomolecule-modified polymer scaffold.Type: GrantFiled: March 8, 2018Date of Patent: January 23, 2024Assignee: REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Lonnie D. Shea, Michael Skoumal, Ryan M. Pearson
-
Patent number: 11872214Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: December 14, 2022Date of Patent: January 16, 2024Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11857595Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.Type: GrantFiled: April 15, 2022Date of Patent: January 2, 2024Assignee: Amryt Endo, Inc.Inventors: Roni Mamluk, Sam Teichman
-
Patent number: 11850260Abstract: A medicinal nanocomposite is provided. The medicinal nanocomposite includes 80 to 99 wt. % carrier particles of a porous silicate material selected from a group including mesoporous silica, silicalite, mesosilicalite, silver-incorporated silicalite, and silver- incorporated mesosilicalite, the carrier particles comprising a pore framework, 0.5 to 10 wt. % silver nanoparticles (Ag NPs) disposed on the pore framework, and 0.5 to 10 wt. % of a platinum-containing pharmaceutical compound disposed on at least one surface selected from an interior pore surface of the carrier particles, an exterior surface of the carrier particles, and a surface of the silver nanoparticles. The medicinal nanocomposite releases less than 10 mole % of the platinum-containing pharmaceutical compound after 60 to 84 hours at a pH of 4.5 to 7, based on an initial amount of the platinum-containing pharmaceutical compound present in the medicinal nanocomposite.Type: GrantFiled: February 4, 2022Date of Patent: December 26, 2023Assignee: Imam Abdulrahman Bin Faisal UniversityInventors: B. Rabindran Jermy, Vijaya Ravinayagam, Suriya Rehman
-
Patent number: 11844783Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: December 14, 2022Date of Patent: December 19, 2023Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11826469Abstract: Provided herein are methods of treatment, compositions, systems and kits using polymer particles as restraints of neutrophil function. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be implicated. In some embodiments, polymer particles are useful for diagnosing neutrophil related diseases or conditions.Type: GrantFiled: September 22, 2021Date of Patent: November 28, 2023Assignee: The Regents of the University of MichiganInventors: Omolola Eniola-Adefeso, William Kelley, Theodore Standiford
-
Patent number: 11826428Abstract: The present specification discloses solid solution pharmaceutical compositions comprising hard fats, liquid lipids, and one or more cannabidiols, including a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: GrantFiled: December 2, 2021Date of Patent: November 28, 2023Assignee: Infirst Healthcare LimitedInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Patent number: 11813348Abstract: The present disclosure relates to a supramolecular preparation of retinol and derivatives thereof and a preparation method therefor, wherein the supramolecular preparation consists of following components in percentage by mass: 3.00-25.0% of retinol and derivatives thereof, 36.5-91.0% of hydroxypropyl ?-cyclodextrin, 4.00-32.0% of hydroxypropyl methylcellulose stearoxy ether, and 2.00-8.0% of PEG/PPG/polybutylene glycol-8/5/3 glycerin, wherein the mass ratio of the PEG/PPG/polybutylene glycol-8/5/3 glycerin to the hydroxypropyl methylcellulose stearoxy ether is 1:2-4. The supramolecular preparation of retinol and derivatives thereof obtained in the present disclosure has the advantages such as good stability, high solubility, low irritation, and good anti-wrinkle effect.Type: GrantFiled: October 28, 2019Date of Patent: November 14, 2023Assignee: PROYA COSMETICS CO., LTD.Inventor: Hanning Wang
-
Patent number: 11801167Abstract: Systems, methods, and apparatuses for generating and releasing iodine are described. Some embodiments may include a dressing member including a plurality of iodine-forming reagents and a water-swellable material. In some embodiments, the dressing member may include water-swellable fibers. The water-swellable fibers may each include a water-swellable material in which iodine-forming reagents are dispersed. As liquid comes into contact with and is absorbed by the water-swellable material, the iodine-forming reagents may come into contact with each other, causing an iodine-forming reaction to occur, producing iodine.Type: GrantFiled: July 16, 2021Date of Patent: October 31, 2023Assignee: KCI Licensing, Inc.Inventors: Timothy Mark Robinson, Brian Andrews, Christopher Brian Locke
-
Patent number: 11801230Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclitaxel and derivatives thereof, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.Type: GrantFiled: February 25, 2021Date of Patent: October 31, 2023Assignees: ANP Technologies, Inc., Fulgent Therapeutics, Inc.Inventors: Ray Yin, Jing Pan, Yubei Zhang, Bingsen Zhou, Yun Yen